AlphaMark Advisors LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

AlphaMark Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% in the fourth quarter, Holdings Channel reports. The firm owned 3,350 shares of the company’s stock after acquiring an additional 200 shares during the period. AlphaMark Advisors LLC’s holdings in Novo Nordisk A/S were worth $288,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of NVO. Raymond James & Associates increased its position in shares of Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares in the last quarter. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the period. International Assets Investment Management LLC increased its holdings in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. LPL Financial LLC raised its position in Novo Nordisk A/S by 3.6% in the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the period. Finally, Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S during the third quarter worth about $98,765,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

Shares of NYSE:NVO opened at $87.94 on Friday. The firm has a market cap of $394.65 billion, a PE ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a fifty day simple moving average of $95.35 and a 200 day simple moving average of $115.17. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.